These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 29272564)
1. Mechanisms of Action and Clinical Development of Elotuzumab. Ritchie D; Colonna M Clin Transl Sci; 2018 May; 11(3):261-266. PubMed ID: 29272564 [No Abstract] [Full Text] [Related]
2. Elotuzumab: First Global Approval. Markham A Drugs; 2016 Mar; 76(3):397-403. PubMed ID: 26809244 [TBL] [Abstract][Full Text] [Related]
3. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma. Pazina T; James AM; Colby KB; Yang Y; Gale A; Jhatakia A; Kearney AY; Graziano RF; Bezman NA; Robbins MD; Cohen AD; Campbell KS Cancer Immunol Res; 2019 Oct; 7(10):1633-1646. PubMed ID: 31431433 [TBL] [Abstract][Full Text] [Related]
4. Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma. Friend R; Bhutani M; Voorhees PM; Usmani SZ Drug Des Devel Ther; 2017; 11():893-900. PubMed ID: 28356715 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Campbell KS; Cohen AD; Pazina T Front Immunol; 2018; 9():2551. PubMed ID: 30455698 [TBL] [Abstract][Full Text] [Related]
6. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882 [TBL] [Abstract][Full Text] [Related]
7. Elotuzumab in the treatment of relapsed and refractory multiple myeloma. Grosicki S; Bednarczyk M; Barchnicka A; Grosicka O Future Oncol; 2021 May; 17(13):1581-1591. PubMed ID: 33478270 [TBL] [Abstract][Full Text] [Related]
8. Elotuzumab May Slow Multiple Myeloma. Cancer Discov; 2015 Jul; 5(7):OF10. PubMed ID: 25998398 [No Abstract] [Full Text] [Related]
9. Elotuzumab for the treatment of multiple myeloma. Wang Y; Sanchez L; Siegel DS; Wang ML J Hematol Oncol; 2016 Jul; 9(1):55. PubMed ID: 27417553 [TBL] [Abstract][Full Text] [Related]
10. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma. Palumbo A; Sonneveld P Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331 [TBL] [Abstract][Full Text] [Related]
11. Elotuzumab as a novel anti-myeloma immunotherapy. Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269 [TBL] [Abstract][Full Text] [Related]